Spermidine Anti-Hypertension Study

• Status: Recruiting
• Trial end date: 2022-11-15
• Target enrollment: 0
• Participant gender: All

Summary

The impact of daily spermidine application on arterial blood pressure and other secondary parameters will be evaluated in a double-blind single center 46 patients cross-over study.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Medical University of Graz
• Collaborators: ETH Zurich; Institut National de la Santé Et de la Recherche Médicale, France; University Hospital Tuebingen; University of Graz

Criteria

Inclusion Criteria:

• Able to provide signed and dated informed consent form

• Persistant arterial hypertension with systolic blood pressure above 150 mmHg during hospitalisation and the day of randomisation

• Stable anti-hypertensive medication with at least two guideline-recommended anti-hypertensive drugs

Exclusion Criteria:

• Systolic blood pressure ≥180mmHg on the day of randomisation

• Spermidine intolerance

• Significant renal impairment defined as glomerular filtration rate < 45ml/min

• Insulin-dependent diabetes mellitus (IDDM)

• Wheat allergy or gluten intolerance

• Life expectancy of less than 12 months

• Participation in another clinical trial